517 - Maternal RSV Vaccination and Infant Nirsevimab Coverage among Infants Born in the 2023-2024 Respiratory Virus Season in a Large Integrated Healthcare System

Saturday, October 19, 2024

11:00 AM – 11:15 AM US PT

Location: 404 AB

Presenting Author(s)

KJ

Karen B. Jacobson, MD, MPH

Kaiser Permanente Vaccine Study Center
Oakland, California, United States

Slides

Co-Author(s)

AW

Andrew J. Watson, MA, MS

Kaiser Permanente Vaccine Study Center
Oakland, California, United States
MM

Maqdooda Merchant, MSc

Kaiser Permanente Vaccine Study Center
Oakland, California, United States
BF

Bruce Fireman, MA

Research Scientist
Division of Research Kaiser Permanente Vaccine Study Center
Oakland, California, United States
Ousseny Zerbo, PhD

Research Scientist
Division of Research Kaiser Permanente Vaccine Study Center
Oakland, CA, United States
Nicola P. Klein, MD, PhD (she/her/hers)

Director, Kaiser Permanente Vaccine Study Center and Senior Research Scientist
Division of Research Kaiser Permanente Vaccine Study Center
Oakland, California, United States

Disclosure(s):

Andrew J. Watson, MA, MS: No financial relationships to disclose

Maqdooda Merchant, MSc: No financial relationships to disclose

Ousseny Zerbo, PhD: No financial relationships to disclose

Nicola P. Klein, MD, PhD: GlaxoSmithKline: Grant/Research Support; Merck: Grant/Research Support; Pfizer: Grant/Research Support; Sanofi Pasteur: Grant/Research Support; Seqirus: Grant/Research Support